Huntington's Disease Induced Cardiac Amyloidosis Is Reversed by Modulating Protein Folding and Oxidative Stress Pathways in the Heart

English version České info

Amyloid-like inclusions have been associated with Huntington's disease (HD), which is caused by expanded polyglutamine repeats in the Huntingtin protein. HD patients exhibit a high incidence of cardiovascular events, presumably as a result of accumulation of toxic amyloid-like inclusions. We have generated a Drosophila model of cardiac amyloidosis that exhibits accumulation of PolyQ aggregates and oxidative stress in myocardial cells, upon heart-specific expression of Huntingtin protein fragments (Htt-PolyQ) with disease-causing poly-glutamine repeats (PolyQ-46, PolyQ-72, and PolyQ-102). Cardiac expression of GFP-tagged Htt-PolyQs resulted in PolyQ length-dependent functional defects that included increased incidence of arrhythmias and extreme cardiac dilation, accompanied by a significant decrease in contractility. Structural and ultrastructural analysis of the myocardial cells revealed reduced myofibrillar content, myofibrillar disorganization, mitochondrial defects and the presence of PolyQ-GFP positive aggregates. Cardiac-specific expression of disease causing Poly-Q also shortens lifespan of flies dramatically. To further confirm the involvement of oxidative stress or protein unfolding and to understand the mechanism of PolyQ induced cardiomyopathy, we co-expressed expanded PolyQ-72 with the antioxidant superoxide dismutase (SOD) or the myosin chaperone UNC-45. Co-expression of SOD suppressed PolyQ-72 induced mitochondrial defects and partially suppressed aggregation as well as myofibrillar disorganization. However, co-expression of UNC-45 dramatically suppressed PolyQ-72 induced aggregation and partially suppressed myofibrillar disorganization. Moreover, co-expression of both UNC-45 and SOD more efficiently suppressed GFP-positive aggregates, myofibrillar disorganization and physiological cardiac defects induced by PolyQ-72 than did either treatment alone. Our results demonstrate that mutant-PolyQ induces aggregates, disrupts the sarcomeric organization of contractile proteins, leads to mitochondrial dysfunction and increases oxidative stress in cardiomyocytes leading to abnormal cardiac function. We conclude that modulation of both protein unfolding and oxidative stress pathways in the Drosophila heart model can ameliorate the detrimental PolyQ effects, thus providing unique insights into the genetic mechanisms underlying amyloid-induced cardiac failure in HD patients.

Vyšlo v časopise: Huntington's Disease Induced Cardiac Amyloidosis Is Reversed by Modulating Protein Folding and Oxidative Stress Pathways in the Heart. PLoS Genet 9(12): e32767. doi:10.1371/journal.pgen.1004024
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004024

Souhrn

Zdroje

1. MerliniG, BellottiV (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349: 583–596.

2. MuchowskiPJ (2002) Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35: 9–12.

3. MackayTF, AnholtRR (2006) Of flies and man: Drosophila as a model for human complex traits. Annu Rev Genomics Hum Genet 7: 339–367.

4. RubinszteinDC, CarmichaelJ (2003) Huntington's disease: molecular basis of neurodegeneration. Expert Rev Mol Med 5: 1–21.

5. ZhangS, BinariR, ZhouR, PerrimonN (2010) A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 184: 1165–1179.

6. SchulteJ, SeppKJ, WuC, HongP, LittletonJT (2011) High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS One 6: e23841.

7. La Spada AR, Weydt P, Pineda VV (2011) Huntington's Disease Pathogenesis: Mechanisms and Pathways. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press, Chapter 2. Frontiers in Neuroscience.

8. LanskaDJ, LavineL, LanskaMJ, SchoenbergBS (1988) Huntington's disease mortality in the United States. Neurology 38: 769–772.

9. SorensenSA, FengerK (1992) Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 29: 911–914.

10. MihmMJ, AmannDM, SchanbacherBL, AltschuldRA, BauerJA, et al. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 25: 297–308.

11. van der BurgJM, BjorkqvistM, BrundinP (2009) Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 8: 765–774.

12. LakhaniVV, DingF, DokholyanNV (2010) Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Comput Biol 6: e1000772.

13. ArrasateM, FinkbeinerS (2012) Protein aggregates in Huntington's disease. Exp Neurol 238: 1–11.

14. GuptaS, JieS, ColbyDW (2012) Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay. J Biol Chem 287: 9982–9989.

15. HattersDM (2008) Protein misfolding inside cells: the case of huntingtin and Huntington's disease. IUBMB Life 60: 724–728.

16. SathasivamK, HobbsC, TurmaineM, MangiariniL, MahalA, et al. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8: 813–822.

17. MoffittH, McPhailGD, WoodmanB, HobbsC, BatesGP (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 4: e8025.

18. BradfordJW, LiS, LiXJ (2010) Polyglutamine toxicity in non-neuronal cells. Cell Res 20: 400–407.

19. StrandAD, AragakiAK, ShawD, BirdT, HoltonJ, et al. (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 14: 1863–1876.

20. ChiuE, AlexanderL (1982) Causes of death in Huntington's disease. Med J Aust 1: 153.

21. PattisonJS, RobbinsJ (2008) Protein misfolding and cardiac disease: establishing cause and effect. Autophagy 4: 821–823.

22. KiriazisH, JenningsNL, DavernP, LambertG, SuY, et al. (2012) Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. J Physiol 590: 5845–5860.

23. SanbeA, OsinskaH, VillaC, GulickJ, KlevitskyR, et al. (2005) Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A 102: 13592–13597.

24. BodmerR, VenkateshTV (1998) Heart development in Drosophila and vertebrates: conservation of molecular mechanisms. Dev Genet 22: 181–186.

25. CrippsRM, OlsonEN (2002) Control of cardiac development by an evolutionarily conserved transcriptional network. Dev Biol 246: 14–28.

26. WolfMJ, RockmanHA (2008) Drosophila melanogaster as a model system for genetics of postnatal cardiac function. Drug Discov Today Dis Models 5: 117–123.

27. OcorrK, ReevesNL, WessellsRJ, FinkM, ChenHS, et al. (2007) KCNQ potassium channel mutations cause cardiac arrhythmias in Drosophila that mimic the effects of aging. Proc Natl Acad Sci U S A 104: 3943–3948.

28. MelkaniGC, BodmerR, OcorrK, BernsteinSI (2011) The UNC-45 chaperone is critical for establishing myosin-based myofibrillar organization and cardiac contractility in the Drosophila heart model. PLoS One 6: e22579.

29. FinkM, Callol-MassotC, ChuA, Ruiz-LozanoP, Izpisua BelmonteJC, et al. (2009) A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. Biotechniques 46: 101–113.

30. NovoselovaTV, MargulisBA, NovoselovSS, SapozhnikovAM, van der SpuyJ, et al. (2005) Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. J Neurochem 94: 597–606.

31. PattisonJS, SanbeA, MaloyanA, OsinskaH, KlevitskyR, et al. (2008) Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 117: 2743–2751.

32. SarparantaJ, JonsonPH, GolzioC, SandellS, LuqueH, et al. (2012) Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 44: 450–452, 450-455, S451-452.

33. LehmacherC, AbelnB, PaululatA (2012) The ultrastructure of Drosophila heart cells. Arthropod Struct Dev 41: 459–474.

34. CostaV, GiacomelloM, HudecR, LopreiatoR, ErmakG, et al. (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med 2: 490–503.

35. DornGW2nd, ClarkCF, EschenbacherWH, KangMY, EngelhardJT, et al. (2011) MARF and Opa1 control mitochondrial and cardiac function in Drosophila. Circ Res 108: 12–17.

36. ShenT, ZhengM, CaoC, ChenC, TangJ, et al. (2007) Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis. J Biol Chem 282: 23354–23361.

37. VosMJ, ZijlstraMP, KanonB, van Waarde-VerhagenMA, BruntER, et al. (2010) HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones. Hum Mol Genet 19: 4677–4693.

38. WillisMS, PattersonC (2013) Proteotoxicity and cardiac dysfunction–Alzheimer's disease of the heart? N Engl J Med 368: 455–464.

39. BarralJM, HutagalungAH, BrinkerA, HartlFU, EpsteinHF (2002) Role of the myosin assembly protein UNC-45 as a molecular chaperone for myosin. Science 295: 669–671.

40. TakahashiM, DoreS, FerrisCD, TomitaT, SawaA, et al. (2000) Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 28: 461–473.

41. FirdausWJ, WyttenbachA, Diaz-LatoudC, CurrieRW, ArrigoAP (2006) Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant. Febs J 273: 3076–3093.

42. GoswamiA, DikshitP, MishraA, MulherkarS, NukinaN, et al. (2006) Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun 342: 184–190.

43. BrowneSE, BowlingAC, MacGarveyU, BaikMJ, BergerSC, et al. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646–653.

44. SantamariaA, Perez-SeverianoF, Rodriguez-MartinezE, MaldonadoPD, Pedraza-ChaverriJ, et al. (2001) Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. Neurochem Res 26: 419–424.

45. SorollaMA, Reverter-BranchatG, TamaritJ, FerrerI, RosJ, et al. (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45: 667–678.

46. ParkYN, ZhaoX, NortonM, TaylorJP, EisenbergE, et al. (2012) Huntingtin fragments and SOD1 mutants form soluble oligomers in the cell. PLoS One 7: e40329.

47. ShenX, ZhengS, MetreveliNS, EpsteinPN (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55: 798–805.

48. WangD, QianL, XiongH, LiuJ, NeckameyerWS, et al. (2006) Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci U S A 103: 13520–13525.

49. JangJH, SurhYJ (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34: 1100–1110.

50. LiuM, LiuF (2011) Resveratrol inhibits mTOR signaling by targeting DEPTOR. Commun Integr Biol 4: 382–384.

51. MaherP, DarguschR, BodaiL, GerardPE, PurcellJM, et al. (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20: 261–270.

52. SpanierG, XuH, XiaN, TobiasS, DengS, et al. (2009) Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60 Suppl 4: 111–116.

53. ZhangC, FengY, QuS, WeiX, ZhuH, et al. (2011) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90: 538–545.

54. ZhongLM, ZongY, SunL, GuoJZ, ZhangW, et al. (2012) Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One 7: e32195.

55. SuhrST, SenutMC, WhiteleggeJP, FaullKF, CuizonDB, et al. (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 153: 283–294.

56. MorleyJF, BrignullHR, WeyersJJ, MorimotoRI (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 99: 10417–10422.

57. ConnorMK, BezborodovaO, EscobarCP, HoodDA (2000) Effect of contractile activity on protein turnover in skeletal muscle mitochondrial subfractions. J Appl Physiol 88: 1601–1606.

58. MaloyanA, SanbeA, OsinskaH, WestfallM, RobinsonD, et al. (2005) Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation 112: 3451–3461.

59. MaloyanA, OsinskaH, LammerdingJ, LeeRT, CingolaniOH, et al. (2009) Biochemical and mechanical dysfunction in a mouse model of desmin-related myopathy. Circ Res 104: 1021–1028.

60. McLendonPM, RobbinsJ (2011) Desmin-related cardiomyopathy: an unfolding story. Am J Physiol Heart Circ Physiol 301: H1220–1228.

61. ShirendebU, ReddyAP, ManczakM, CalkinsMJ, MaoP, et al. (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 20: 1438–1455.

62. GalluzziL, KeppO, Trojel-HansenC, KroemerG (2012) Mitochondrial control of cellular life, stress, and death. Circ Res 111: 1198–1207.

63. MelovS, SchneiderJA, DayBJ, HinerfeldD, CoskunP, et al. (1998) A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 18: 159–163.

64. SanbeA, OsinskaH, SaffitzJE, GlabeCG, KayedR, et al. (2004) Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 101: 10132–10136.

65. SaftC, ZangeJ, AndrichJ, MullerK, LindenbergK, et al. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 20: 674–679.

66. LoPC, ZaffranS, SenatoreS, FraschM (2007) The Drosophila Hand gene is required for remodeling of the developing adult heart and midgut during metamorphosis. Dev Biol 311: 287–296.

67. HanZ, OlsonEN (2005) Hand is a direct target of Tinman and GATA factors during Drosophila cardiogenesis and hematopoiesis. Development 132: 3525–3536.

68. HanZ, YiP, LiX, OlsonEN (2006) Hand, an evolutionarily conserved bHLH transcription factor required for Drosophila cardiogenesis and hematopoiesis. Development 133: 1175–1182.

69. LeeCF, MelkaniGC, YuQ, SuggsJA, KronertWA, et al. (2011) Drosophila UNC-45 accumulates in embryonic blastoderm and in muscles, and is essential for muscle myosin stability. J Cell Sci 124: 699–705.

70. ThomeniusM, FreelCD, HornS, KrieserR, AbdelwahidE, et al. (2011) Mitochondrial fusion is regulated by Reaper to modulate Drosophila programmed cell death. Cell Death Differ 18: 1640–1650.

71. DuBoffB, GotzJ, FeanyMB (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75: 618–632.

72. OcorrK, FinkM, CammaratoA, BernsteinS, BodmerR (2009) Semi-automated Optical Heartbeat Analysis of small hearts. J Vis Exp 31: 1435.

73. Taghli-LamallemO, AkasakaT, HoggG, NudelU, YaffeD, et al. (2008) Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype. Aging Cell 7: 237–249.

74. AlayariNN, VoglerG, Taghli-LamallemO, OcorrK, BodmerR, et al. (2009) Fluorescent labeling of Drosophila heart structures. J Vis Exp 32: 1423.

75. HabermanAS, AkbarMA, RayS, KramerH (2010) Drosophila acinus encodes a novel regulator of endocytic and autophagic trafficking. Development 137: 2157–2166.

76. CammaratoA, AhrensCH, AlayariNN, QeliE, RuckerJ, et al. (2011) A mighty small heart: the cardiac proteome of adult Drosophila melanogaster. PLoS One 6: e18497.

77. SatoT (1968) A modified method for lead staining of thin sections. J Electron Microsc (Tokyo) 17: 158–159.